

## References

- Al-Aly, Z., & Topol, E. (2024a). Solving the puzzle of Long Covid. *Science*, 383(6685), 830–832. <https://doi.org/10.1126/science.adl0867>
- Al-Aly, Z., & Topol, E. (2024b). Solving the puzzle of Long Covid. *Science*, 383(6685), 830–832. <https://doi.org/10.1126/science.adl0867>
- Al-Aly, Z., Davis, H., McCorkell, L., Soares, L., Wulf-Hanson, S., Iwasaki, A., & Topol, E. J. (2024). Long Covid Science, research and policy. *Nature Medicine*, 30(8), 2148–2164. <https://doi.org/10.1038/s41591-024-03173-6>
- Ashraf, N., Abou Shaar, B., Taha, R. M., Arabi, T. Z., Sabbah, B. N., Alkodaymi, M. S., Omrani, O. A., Makhzoum, T., Almahfoudh, N. E., Al-Hammad, Q. A., Hejazi, W., Obeidat, Y., Osman, N., Al-Kattan, K. M., Berbari, E. F., & Tleyjeh, I. M. (2023). A systematic review of trials currently investigating therapeutic modalities for post-acute covid-19 syndrome and registered on WHO International Clinical Trials Platform. *Clinical Microbiology and Infection*, 29(5), 570–577. <https://doi.org/10.1016/j.cmi.2023.01.007>
- Bonilla, H., Tian, L., Marconi, V. C., Shafer, R., McComsey, G. A., Miglis, M., Yang, P., Bonilla, A., Eggert, L., & Geng, L. N. (2023). Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. *International Immunopharmacology*, 124, 110966. <https://doi.org/10.1016/j.intimp.2023.110966>
- Brown, K. A., Langford, B., Schwartz, K. L., Diong, C., Garber, G., & Daneman, N. (2020). Antibiotic prescribing choices and their comparative *C. difficile* infection risks: A longitudinal case-cohort study. *Clinical Infectious Diseases*, 72(5), 836–844. <https://doi.org/10.1093/cid/ciaa124>

Buffie, C. G., & Pamer, E. G. (2013). Microbiota-mediated colonization resistance against intestinal pathogens. *Nature Reviews Immunology*, 13(11), 790–801.

<https://doi.org/10.1038/nri3535>

*C. Auris Quicksheet - CDPH*. California Department of Public Health. (n.d.-a).

[https://www.cdph.ca.gov/Programs/CHCQ/HAI/CDPH%20Document%20Library/CaurisQuicksheet\\_Only.pdf](https://www.cdph.ca.gov/Programs/CHCQ/HAI/CDPH%20Document%20Library/CaurisQuicksheet_Only.pdf)

Camero, K. (2025, March 13). *5 years later, Long Covid is still a medical mystery: What*

*scientists have learned*. NBCNews.com. [https://www.nbcnews.com/health/health-](https://www.nbcnews.com/health/health-news/5-years-later-long-covid-still-medical-mystery-scientists-learned-rcna195608)

[news/5-years-later-long-covid-still-medical-mystery-scientists-learned-rcna195608](https://www.nbcnews.com/health/health-news/5-years-later-long-covid-still-medical-mystery-scientists-learned-rcna195608)

Centers for Disease Control and Prevention. (2024, October 3). *Long Covid - Household Pulse survey - covid-19*. Centers for Disease Control and Prevention.

<https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm>

Centers for Disease Control and Prevention. (2025). *Medical tourism*. Centers for Disease

Control and Prevention. [https://www.cdc.gov/yellow-book/hcp/health-care-](https://www.cdc.gov/yellow-book/hcp/health-care-abroad/medical-tourism.html)

[abroad/medical-tourism.html](https://www.cdc.gov/yellow-book/hcp/health-care-abroad/medical-tourism.html)

Centers for Disease Control and Prevention. (n.d.-a). *National Center for Health Statistics*.

Centers for Disease Control and Prevention. <https://www.cdc.gov/nchs/index.html>

Centers for Disease Control and Prevention. (n.d.-b). *Tracking C. Auris*. Centers for Disease

Control and Prevention. <https://www.cdc.gov/candida-auris/tracking-c-auris/index.html>

Chilton, C. H., Pickering, D. S., & Freeman, J. (2018). Microbiologic factors affecting

clostridium difficile recurrence. *Clinical Microbiology and Infection*, 24(5), 476–482.

<https://doi.org/10.1016/j.cmi.2017.11.017>

Ciwun, M., Tankiewicz-Kwedlo, A., & Pawlak, D. (2024). Low-dose naltrexone as an adjuvant in combined anticancer therapy. *Cancers*, *16*(6), 1240.

<https://doi.org/10.3390/cancers16061240>

*CPO Laboratory Testing*. CDPH: CPO Laboratory Testing. (n.d.).

<https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/CPOLabTesting.aspx>

*CPO Quicksheet - CDPH*. California Department of Public Health. (n.d.-b).

[https://www.cdph.ca.gov/Programs/CHCQ/HAI/CDPH%20Document%20Library/CPOQuicksheet\\_Only.pdf](https://www.cdph.ca.gov/Programs/CHCQ/HAI/CDPH%20Document%20Library/CPOQuicksheet_Only.pdf)

Darby, E. M., Trampari, E., Siasat, P., Gaya, M. S., Alav, I., Webber, M. A., & Blair, J. M.

(2022). Molecular mechanisms of antibiotic resistance revisited. *Nature Reviews*

*Microbiology*, *21*(5), 280–295. <https://doi.org/10.1038/s41579-022-00820-y>

Devinney, K., Burton, N., Alroy, K. A., Crawley, A., Da Costa-Carter, C.-A., Kratz, M. M., Lin,

Y., Montfort-Gardeazabal, J., Portier, T., Santiago, C., Siemetzki-Kapoor, U., Sullivan,

M., Wiegartner, R. J., McPherson, T. D., & Greendyke, W. G. (2025). *notes from the*

*field*: Increase in New Delhi metallo- $\beta$ -lactamase–producing carbapenem-resistant

enterobacterales — New York City, 2019–2024. *MMWR. Morbidity and Mortality*

*Weekly Report*, *74*(23), 401–403. <https://doi.org/10.15585/mmwr.mm7423a2>

Ely, E. W., Brown, L. M., & Fineberg, H. V. (2024). Long covid defined. *New England Journal*

*of Medicine*, *391*(18), 1746–1753. <https://doi.org/10.1056/nejmsb2408466>

Erlandson, K., Geng, L., Selvaggi, C., & Thaweethai, T. (2024). Differentiation of Prior SARS-

CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements

in the RECOVER Cohort. *American College of Physicians*.

Freeman, J., Vernon, J., Pilling, S., Morris, K., Nicholson, S., Shearman, S., Longshaw, C., & Wilcox, M. H. (2018). The closer study: Results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent clostridium difficile ribotypes, 2011–2014. *Clinical Microbiology and Infection*, 24(7), 724–731.  
<https://doi.org/10.1016/j.cmi.2017.10.008>

Ganeshkumar, A., Muthuselvam, M., Lima, P. M., Rajaram, R., & Junqueira, J. C. (2024). Current perspectives of antifungal therapy: A special focus on candida auris. *Journal of Fungi*, 10(6), 408. <https://doi.org/10.3390/jof10060408>

Garrigues, J. M., Gray, H. K., Ison, R. P., Uslan, D. Z., Lima, A., Gonzalez-Ferrer, S., Trejo, M., Zhuo, R., Matysiak Match, C. J., Ulloa, E. R., Bhaurla, S., Lewis, V., Parti, U., Sandoval, T., Turay, S., Walton, S., Prabaker, K., Garner, O. B., Chandrasekaran, S., ... Yang, S. (2025). Outbreak of New Delhi metallo- $\beta$ -lactamase carbapenemase-producing pseudomonas aeruginosa infections in a southern California hospital. *American Journal of Infection Control*, 53(9), 977–984. <https://doi.org/10.1016/j.ajic.2025.06.005>

Geng, L. N., Bonilla, H., Hedlin, H., Jacobson, K. B., Tian, L., Jagannathan, P., Yang, P. C., Subramanian, A. K., Liang, J. W., Shen, S., Deng, Y., Shaw, B. J., Botzheim, B., Desai, M., Pathak, D., Jazayeri, Y., Thai, D., O'Donnell, A., Mohaptra, S., ... Singh, U. (2024). Nirmatrelovir-ritonavir and symptoms in adults with postacute sequelae of SARS-COV-2 infection. *JAMA Internal Medicine*, 184(9), 1024.  
<https://doi.org/10.1001/jamainternmed.2024.2007>

Goldowitz, I., Worku, T., Brown, L., & Fineberg, H. V. (2024). *A Long Covid Definition*.  
<https://doi.org/10.17226/27768>

Greenhalgh, T., Sivan, M., Perlowski, A., & Nikolich, J. (2024). Long Covid: A clinical update.

*The Lancet*, 404(10453), 707–724. [https://doi.org/10.1016/s0140-6736\(24\)01136-x](https://doi.org/10.1016/s0140-6736(24)01136-x)

Guery, B., Menichetti, F., Anttila, V.-J., Adomakoh, N., Aguado, J. M., Bisnauthsing, K.,

Georgopali, A., Goldenberg, S. D., Karas, A., Kazeem, G., Longshaw, C., Palacios-

Fabrega, J. A., Cornely, O. A., & Vehreschild, M. J. (2018). Extended-pulsed

fidaxomicin versus vancomycin for clostridium difficile infection in patients 60 years and

older (extend): A randomised, controlled, open-label, phase 3B/4 trial. *The Lancet*

*Infectious Diseases*, 18(3), 296–307. [https://doi.org/10.1016/s1473-3099\(17\)30751-x](https://doi.org/10.1016/s1473-3099(17)30751-x)

Gupta, A., & Khanna, S. (2016). Repeat *clostridium difficile* testing. *JAMA*, 316(22), 2422.

<https://doi.org/10.1001/jama.2016.17173>

Hennessee, I. P., Forsberg, K., Beekmann, S. E., Polgreen, P. M., Gold, J. A. W., & Lyman, M.

(2024). *candida auris* screening practices at healthcare facilities in the United States: An

emerging infections network survey. *Infection Control & Hospital Epidemiology*,

45(6), 766–769. <https://doi.org/10.1017/ice.2024.5>

Herrera, G., Paredes-Sabja, D., Patarroyo, M. A., Ramírez, J. D., & Muñoz, M. (2021). Updating

changes in human gut microbial communities associated with *clostridioides*

*difficile* infection. *Gut Microbes*, 13(1).

<https://doi.org/10.1080/19490976.2021.1966277>

Jiang, J., Chan, L., Kauffman, J., Narula, J., Charney, A. W., Oh, W., & Nadkarni, G. (2023).

Impact of vaccination on major adverse cardiovascular events in patients with covid-19

infection. *Journal of the American College of Cardiology*, 81(9), 928–930.

<https://doi.org/10.1016/j.jacc.2022.12.006>

- Jones, C. R., Neill, C., Borman, A. M., Budd, E. L., Cummins, M., Fry, C., Guy, R. L., Jeffery, K., Johnson, E. M., Manuel, R., Mirfenderesky, M., Moore, G., Patel, B., Schelenz, S., Staniforth, K., Taori, S. K., & Brown, C. S. (2024). The laboratory investigation, management, and Infection Prevention and control of candida auris: A narrative review to inform the 2024 national guidance update in England. *Journal of Medical Microbiology*, 73(5). <https://doi.org/10.1099/jmm.0.001820>
- Linda, G., Erlandson, K., Hornig, M., Letts, R., Selvaggi, C., & Ashktorab, H. (2025). 2024 Update of the RECOVER-Adult Long COVID Research Index. *JAMA*, 333(8). <https://doi.org/10.1001/jama.2024.24184>.
- Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P. A., Cuapio, A., & Villapol, S. (2021). More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. *Scientific Reports*, 11(1). <https://doi.org/10.1038/s41598-021-95565-8>
- Lyman, M., Forsberg, K., Sexton, D. J., Chow, N. A., Lockhart, S. R., Jackson, B. R., & Chiller, T. (2023). Worsening spread of *candida auris* in the United States, 2019 to 2021. *Annals of Internal Medicine*, 176(4), 489–495. <https://doi.org/10.7326/m22-3469>
- López, L. F., Arenas, S., Jimenez, A., Ferreira, T. B., Parekh, D. J., Bracho Rincon, O., Farinas, M., Lyman, M., Litvintseva, A. P., Shukla, B. S., & Sexton, D. J. (2025). Improved consistency of *candida auris* colonization screening with an anterior nares and hands composite sample. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaf365>
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H. (2018). Clinical practice guidelines for clostridium

difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

*Clinical Infectious Diseases*, 66(7). <https://doi.org/10.1093/cid/cix1085>

Nelson, R. L., Suda, K. J., & Evans, C. T. (2017a). Antibiotic treatment for *clostridium difficile* - associated diarrhoea in adults. *Cochrane Database of Systematic Reviews*, 2017(3).  
<https://doi.org/10.1002/14651858.cd004610.pub5>

Nelson, R. L., Suda, K. J., & Evans, C. T. (2017b). Antibiotic treatment for *clostridium difficile* - associated diarrhoea in adults. *Cochrane Database of Systematic Reviews*, 2017(3).  
<https://doi.org/10.1002/14651858.cd004610.pub5>

Oikonomou, V., Smith, G., Constantine, G. M., Schmitt, M. M., Ferré, E. M. N., Alejo, J. C., Riley, D., Kumar, D., Dos Santos Dias, L., Pechacek, J., Hadjiyannis, Y., Webb, T., Seifert, B. A., Ghosh, R., Walkiewicz, M., Martin, D., Besnard, M., Snarr, B. D., Deljookorani, S., ... Lionakis, M. S. (2024). The role of interferon- $\gamma$  in autoimmune polyendocrine syndrome type 1. *New England Journal of Medicine*, 390(20), 1873–1884.  
<https://doi.org/10.1056/nejmoa2312665>

O’Grady, K., Knight, D. R., & Riley, T. V. (2021). Antimicrobial resistance in *Clostridioides difficile*. *European Journal of Clinical Microbiology & Infectious Diseases*, 40(12), 2459–2478. <https://doi.org/10.1007/s10096-021-04311-5>

Pan, E. (n.d.). *Ongoing transmission of candida auris in healthcare facilities in northern and Central California*. California Department of Public Health.  
<https://www.cdph.ca.gov/Programs/OPA/Pages/CAHAN/Ongoing-Transmission-of-Candida-auris-in-Healthcare-Facilities-in-Northern-and-Central-California-.aspx>

- Polage, C. R., Gyorke, C. E., Kennedy, M. A., Leslie, J. L., Chin, D. L., Wang, S., Nguyen, H. H., Huang, B., Tang, Y.-W., Lee, L. W., Kim, K., Taylor, S., Romano, P. S., Panacek, E. A., Goodell, P. B., Solnick, J. V., & Cohen, S. H. (2015). Overdiagnosis of *Clostridium difficile* infection in the molecular test era. *JAMA Internal Medicine*, 175(11), 1792.  
<https://doi.org/10.1001/jamainternmed.2015.4114>
- Recover clinical trials*. Recover, Researching Covid to Enhance Recovery. (n.d.).  
<https://trials.recovercovid.org/>
- Sader, H. S., Mendes, R. E., Carvalhaes, C. G., Kimbrough, J. H., & Castanheira, M. (2023). Changing epidemiology of carbapenemases among carbapenem-resistant Enterobacterales from United States hospitals and the activity of Aztreonam-avibactam against Contemporary Enterobacterales (2019–2021). *Open Forum Infectious Diseases*, 10(2). <https://doi.org/10.1093/ofid/ofad046>
- Smith, D. J., Misas, E., Gold, J. A., Evert, N., Dang, T., Prot, E., Godwin, S., Rivas, J., Pearson, J., Koenecke, L., Bustamante, N. D., Marinissen, M. J., Rodriguez, G. G., López-Martínez, I., Lutfy, C., Williams, S., Vazquez Deida, A. A., Byrd, K. M., Villalba, J. A., ... Sumimoto, N. (2025). Fungal meningitis in US patients who received epidural anesthesia in Matamoros, Mexico. *Clinical Infectious Diseases*.  
<https://doi.org/10.1093/cid/ciaf399>
- Suphavitai, C., Ko, K. K., Lim, K. M., Tan, M. G., Boonsimma, P., Chu, J. J., Goh, S. S., Rajandran, P., Lee, L. C., Tan, K. Y., Shaik Ismail, B. B., Aung, M. K., Yang, Y., Sim, J. X., Venkatachalam, I., Chong, B. P., Spruijtenburg, B., Chan, K. S., Oon, L. L., ... Nagarajan, N. (2024). Detection and characterisation of a sixth *Candida auris* clade in

Singapore: A genomic and phenotypic study. *The Lancet Microbe*, 5(9), 100878.

[https://doi.org/10.1016/s2666-5247\(24\)00101-0](https://doi.org/10.1016/s2666-5247(24)00101-0)

Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024).

Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. *Clinical Infectious Diseases*.

<https://doi.org/10.1093/cid/ciae403>

van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser,

C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., Speelman, P., Dijkgraaf,

M. G. W., & Keller, J. J. (2013). Duodenal infusion of donor feces for

recurrent *Clostridium difficile*. *New England Journal of Medicine*, 368(5), 407–415.

<https://doi.org/10.1056/nejmoa1205037>

Xie, Y., Choi, T., & Al-Aly, Z. (2023). Association of treatment with Nirmatrelvir and the risk of post-COVID-19 condition. *JAMA Internal Medicine*, 183(6), 554.

<https://doi.org/10.1001/jamainternmed.2023.0743>

Xu, Y., Li, H., Santosa, A., Wettermark, B., Fall, T., Björk, J., Börjesson, M., Gisslén, M., &

Nyberg, F. (2024). Cardiovascular events following coronavirus disease 2019 vaccination in adults: A nationwide Swedish study. *European Heart Journal*, 46(2), 147–157.

<https://doi.org/10.1093/eurheartj/ehae639>

Yotsuyanagi, H., Ohmagari, N., Doi, Y., Yamato, M., Fukushi, A., Imamura, T., Sakaguchi, H.,

Sonoyama, T., Sanaki, T., Ichihashi, G., Tsuge, Y., Uehara, T., & Mukae, H. (2024).

Prevention of post covid-19 condition by early treatment with Ensitrelvir in the phase 3

Scorpio-SR Trial. *Antiviral Research*, 229, 105958.

<https://doi.org/10.1016/j.antiviral.2024.105958>